The fastest-growing and largest of the 20 sized Pharmaceuticals markets in France, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $1 Bn | $8.7 Bn | 23.9% | 19 |
| 2 | Cell Based Immunotherapy | $457 Mn | $3.3 Bn | 22% | 2,091 |
| 3 | Cannabidiol (CBD) | $606 Mn | $2.6 Bn | 15.8% | 14 |
| 4 | Cannabis | $932 Mn | $3 Bn | 12.5% | 49 |
| 5 | Atopic Dermatitis Drugs | $309 Mn | $893 Mn | 11.2% | 32 |
| 6 | Oncology/Cancer Drugs | $4.9 Bn | $9.9 Bn | 7.4% | 2,210 |
| 7 | Anti-Aging | $2.4 Bn | $4.8 Bn | 7.1% | 151 |
| 8 | Diabetes Management | $2.1 Bn | $3.9 Bn | 6.1% | 146 |
| 9 | Alzheimer Drugs | $138 Mn | $242 Mn | 5.8% | 98 |
| 10 | Contraceptives Drugs | $693 Mn | $1.2 Bn | 5.8% | 3 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $4.9 Bn | $9.9 Bn | 7.4% | 2,210 |
| 2 | Anti-Aging | $2.4 Bn | $4.8 Bn | 7.1% | 151 |
| 3 | Diabetes Management | $2.1 Bn | $3.9 Bn | 6.1% | 146 |
| 4 | Gastrointestinal Drugs | $1.5 Bn | $2.1 Bn | 3.6% | 843 |
| 5 | Asthma & COPD Drugs | $1.4 Bn | $1.8 Bn | 3% | 113 |
| 6 | Biosimilars | $1 Bn | $8.7 Bn | 23.9% | 19 |
| 7 | Cannabis | $932 Mn | $3 Bn | 12.5% | 49 |
| 8 | HIV Drugs | $825 Mn | $1.3 Bn | 4.8% | 59 |
| 9 | Contraceptives Drugs | $693 Mn | $1.2 Bn | 5.8% | 3 |
| 10 | Cancer Supportive Care Drugs | $682 Mn | $981 Mn | 3.7% | 399 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 23.9% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (22%).
Oncology/Cancer Drugs is the largest, worth about $4.9 Bn in 2023 and $9.9 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.